Abstract
Background CD-NP (Cenderitide) is the only chimeric natriuretic peptide that acts on both the A and B natriuretic peptide receptors (NPR). This differential mechanism of action reduces the arterial vasodilating properties, while retaining the cardiac unloading and aldosterone inhibiting actions of the NPR-A receptor in addition to the direct anti-remodeling actions of the NPR-B receptor. Our objective is to determine the effects of 3 weeks of sustained delivery of CD-NP via a single subcutaneous (SQ) injection of a fully biodegradable in-situ polymer precipitation delivery system (Gel system) in a model of experimental myocardial infarction (MI).
Highlights
CD-NP (Cenderitide) is the only chimeric natriuretic peptide that acts on both the A and B natriuretic peptide receptors (NPR)
Our objective is to determine the effects of 3 weeks of sustained delivery of CD-NP via a single subcutaneous (SQ) injection of a fully biodegradable in-situ polymer precipitation delivery system (Gel system) in a model of experimental myocardial infarction (MI)
Materials and methods The CD-NP Gel system consists of 0.45% percentage weight/weight (w/w) CD-NP formulated with 40% Poly in 39.55% w/w N-methyl-2pyrrolidinone and 20% w/w triacetin
Summary
CD-NP (Cenderitide) is the only chimeric natriuretic peptide that acts on both the A and B natriuretic peptide receptors (NPR). Our objective is to determine the effects of 3 weeks of sustained delivery of CD-NP via a single subcutaneous (SQ) injection of a fully biodegradable in-situ polymer precipitation delivery system (Gel system) in a model of experimental myocardial infarction (MI)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
